Other Events ·
Apollomics Inc. received a Nasdaq listing deficiency notice on June 18, 2026, because it failed to meet the minimum…
APLMApollomics Inc.
Apollomics Inc. received a Nasdaq listing deficiency notice on June 18, 2026, because it failed to meet the minimum $35 million Market Value of Listed Securities requirement. The company also failed to meet alternative Nasdaq Listing Rules 5550(b)(1) and 5550(b)(3). The company has a 180-day compliance period ending December 15, 2026, to regain compliance. Additionally, effective June 11, 2026, the company terminated its Collaboration and License Agreement with Launxp International Co., Ltd. due to a material breach involving an unpaid $3.8 million upfront payment. A dispute resolution process was initiated on June 18, 2026. Apollomics Inc. is a biotechnology company focused on oncology-related drug discovery and development.